USPTO trademark

WITHZETA

Under examinationUSPTOWord markClass 9Class 42

"WITHZETA" is a word mark owned by Lantern Pharma Inc., filed at the USPTO on January 20, 2026. It is under examination and covers classes 9 and 42.

View Lantern Pharma Inc. portfolioGet this data via the API
Official USPTO record
WITHZETA trademark as filed
As filed with the USPTO
Status
Under examination
Since June 23, 2026
Filed
January 20, 2026
Registered
Not yet
Expires
Not recorded
Application no.
99603537
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
2 classes
Ownership

Who owns WITHZETA

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Lantern Pharma Inc.

LTRN · Dallas, United States

12 trademarks in the portfolioView company

Representative

Nigamnarayan Acharya

Goods and services

What the mark covers

The products and services WITHZETA is filed for, grouped by Nice class.

  • Downloadable computer software for providing computational models and simulations for identifying, evaluating, and prioritizing therapeutic targets, drug candidates, and combination therapies; downloadable artificial intelligence software platform featuring software for hypothesis generation, in silico experimentation, and data-driven scientific discovery in the field of oncology; downloadable computer software for designing, modeling, and optimizing clinical trial concepts and research protocols for research of medical therapies; downloadable computer software for predictive analytics, biomarker discovery, drug response modeling, and validation of scientific hypotheses in the field of oncology

  • Providing temporary use of a non-downloadable artificial intelligence software platform featuring software for {specify the function of the software} in the fields of scientific and biomedical research; providing an online software-as-a-service (SaaS) platform featuring artificial intelligence and machine-learning software for analyzing biological, genomic, proteomic, clinical, and pharmacological data; scientific research services using artificial intelligence in the field of oncology and rare diseases; providing temporary use of a non-downloadable artificial intelligence software platform featuring software for computational models and simulations for identifying, evaluating, and prioritizing therapeutic targets, drug candidates, and combination therapies in the field of oncology; Providing on-line non downloadable software using artificial intelligence (AI) for hypothesis generation, in silico experimentation, and data-driven scientific research in the fields of {specify}; providing an online software-as-a-service (SaaS) platform featuring softwarefor designing, modeling, and optimizing clinical trial concepts and research protocols for investigational medical therapies; providing an online software-as-a-service (SaaS) platform featuring software for predictive analytics, biomarker discovery, drug response modeling, and validation of scientific hypotheses in the fields of oncology; providing scientific data analysis, visualization, and interpretation services using artificial intelligence in the field of oncology;providing an online software-as-a-service (SaaS) platform featuring software for accelerating biomedical research and development of therapeutic drugs through computational model simulations; Providing medical and scientific research information in the field of oncology and rare diseases; providing information and analysis relating to biomedical research and drug discovery, not for the purpose of diagnosis or treatment.

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Notification of letter of suspension e-mailed
  2. Letter of suspension e-mailed
  3. Suspension letter written
  4. Teas/email correspondence entered
  5. Correspondence received in law office
  6. Teas response to office action received
  7. Notification of non-final action e-mailed
  8. Non-final action e-mailed
  9. Non-final action written
  10. Assigned to examiner

3 earlier steps on the official record.

FAQ

About WITHZETA

Who owns the trademark "WITHZETA"?

The USPTO trademark "WITHZETA" (application 99603537) is owned by Lantern Pharma Inc.

What is the status of "WITHZETA"?

Its status at the USPTO is: under examination.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull WITHZETA and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d2b8e-da02-775e-890d-56c74edee1cd
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2b8e-da02-775e-890d-56c74edee1cd",
  "object": "trademark",
  "mark_text": "WITHZETA",
  "status": {
    "primary": "pending",
    "stage": "examining"
  },
  "office_code": "US",
  "application_number": "99603537",
  "filing_date": "2026-01-20",
  "nice_classes": [
    9,
    42
  ],
  "owners": [
    {
      "name": "Lantern Pharma Inc.",
      "entity_id": "ent_019eb717-849f-7289-98eb-8fb06e0056c2"
    }
  ]
}